Moore Capital Management LP Purchases Shares of 44,001 Pharvaris N.V. $PHVS

Moore Capital Management LP acquired a new position in Pharvaris N.V. (NASDAQ:PHVS) in the second quarter, HoldingsChannel reports. The firm acquired 44,001 shares of the company’s stock, valued at approximately $1,522,000.

A number of other institutional investors also recently made changes to their positions in PHVS. Quantbot Technologies LP purchased a new position in shares of Pharvaris in the second quarter worth about $41,000. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. Barclays PLC bought a new position in shares of Pharvaris in the fourth quarter worth approximately $77,000. CoreCap Advisors LLC bought a new stake in Pharvaris in the 2nd quarter worth $93,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Pharvaris in the 4th quarter worth approximately $110,000.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PHVS shares. New Street Research set a $60.00 price objective on shares of Pharvaris in a report on Friday, August 14th. Wells Fargo & Company assumed coverage on Pharvaris in a research report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 target price on the stock. Morgan Stanley boosted their target price on shares of Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.08.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $34.61 on Tuesday. The company has a market cap of $2.26 billion, a P/E ratio of -11.35 and a beta of -2.31. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $38.13. The firm has a 50-day simple moving average of $34.64 and a two-hundred day simple moving average of $30.82.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities research analysts forecast that Pharvaris N.V. will post -3.15 EPS for the current year.

Insiders Place Their Bets

In related news, insider Anne Lesage sold 30,703 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the sale, the insider directly owned 93,969 shares in the company, valued at $3,334,959.81. The trade was a 24.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director owned 315,167 shares of the company’s stock, valued at $11,185,276.83. This trade represents a 8.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 121,325 shares of company stock valued at $4,270,425 over the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.